University of Sorocaba, PhageLab - Laboratory of Biofilms and Bacteriophages.
Pontifical Catholic University of São Paulo.
Medicine (Baltimore). 2021 Mar 12;100(10):e24938. doi: 10.1097/MD.0000000000024938.
: Evacuation disorders are common in industrialized countries, affecting an average of 15% to 20% of the healthy adult population. Probiotic therapy can reduce functional constipation and increase both the number of weekly bowel movements and quality of stools. Based on the hypothesis that a combination of more strains may provide better results for constipation and facilitate adherence to treatment, this study will evaluate the efficacy and safety of a combination of different strains of sp. and sp. in functional constipation.
: A single-centre trial of adults aged 20 to 80 years with intestinal constipation will be conducted at a Gastroenterology Clinic in Sorocaba, State of São Paulo, Brazil. Participants will be allocated into 3 groups receiving: 1. mixture of 3 probiotics: [, , and (3 × 10 CFU)]; 2. mixture of 8 probiotics [, , , , , , (8 × 10 CFU)]; or 3. placebo, for 4 weeks. The outcomes of interest will be change in frequency of weekly bowel movements, change in stool quality according to the 4–6 Bristol scale, number of volunteer withdrawal, number of adverse events and number of serious adverse effect.
: The probiotic products are expected to induce beneficial changes in the intestinal microbiota, thereby increasing intestinal frequency to over 3 times a week and improving stool quality. The results can guide patients and healthcare practitioners and help in decision-making in the treatment of functional constipation.
: ClinicalTrials.gov Identifier: NCT04437147: The Effect of Probiotics on Functional Constipation in Adults: Study protocol for Double blind, Randomized, Placebo controlled Study
: Version 01 August 30, 2020.
在工业化国家,疏散障碍很常见,影响了平均 15%至 20%的健康成年人。益生菌疗法可以减少功能性便秘,并增加每周排便次数和粪便质量。基于更多种菌株组合可能为便秘提供更好的结果并促进对治疗的依从性的假设,本研究将评估不同菌株的组合在功能性便秘中的疗效和安全性。
在巴西圣保罗州索罗卡巴的一家胃肠病诊所,对 20 至 80 岁的有肠道便秘的成年人进行一项单中心试验。参与者将被分配到 3 个组中,分别接受:1. 3 种益生菌混合物:[、和(3×10 CFU)];2. 8 种益生菌混合物[、、、、、、(8×10 CFU)];或 3. 安慰剂,持续 4 周。主要观察指标为每周排便次数的变化、根据 4-6 布里斯托尔量表改变粪便质量、志愿者退出人数、不良事件和严重不良事件的数量。
益生菌产品预计会引起肠道微生物群的有益变化,从而增加肠道频率,每周超过 3 次,并改善粪便质量。研究结果可以为患者和医疗保健从业者提供指导,并有助于功能性便秘治疗的决策。
ClinicalTrials.gov 标识符:NCT04437147:益生菌对成人功能性便秘的影响:双盲、随机、安慰剂对照研究的研究方案
2020 年 8 月 30 日第 01 版。